NOV 28, 2017 06:00 AM PST

WEBINAR: First Look: New Alinity ci-series Systems in Action

SPONSORED BY: Abbott Diagnostics
C.E. CREDITS: P.A.C.E. CE | Florida CE
  • Senior Director, Research and Clinical Systems, Abbott Laboratories
      Jennifer joined Abbott in 2013 as a director of R&D, Abbott Diagnostics. Since joining Abbott, she has become Senior Director, Clinical and Research Systems. In this role, Jennifer is responsible for ARCHITECT and Alinity assay development as well as Immunoassay Third Party Manufacturer (TPM) new product development.

      Prior to joining Abbott, Jennifer was Vice President, Assay Integration and System Development for Nanosphere, Inc. She also held several positions at Baxter Healthcare, including Senior Systems Engineer and Lead System Architect.

      Jennifer attended the University of Illinois at Chicago and received her Bachelor's and Master's degrees in Bioengineering.
    • Global Marketing Manager for Alinity ci-series Systems, Abbott Diagnostics
        Brittany joined Abbott in 2012 as Senior Global Product Manager for Clinical Chemistry. Now the Global Marketing Manager for Alinity ci-series systems, she leads the global marketing team responsible for Alinity ci-series systems and software.

        Brittany earned her Bachelor's degree in Clinical Laboratory Science from Purdue University as well as Master's degrees in Health Administration and Health Education from Indiana University.
      • Global Marketing Manager for Alinity ci-series Immunoassay and Clinical Chemistry Reagents, Abbott Diagnostics
          Jose joined Abbott in 2003 as a Technical Support scientist for Immunoassays on Abbott's legacy platforms, TDx and AxSYM. Since then, he has held several roles throughout the organization, including Operations, R&D, Scientific Affairs in Latin America and Canada, and most recently, Global Marketing. Currently, Jose leads the marketing team responsible for bringing to market assays for the Alinity ci-series.

          Jose received his Bachelor of Science degree in Molecular Biology & Microbiology from the University of Central Florida and a Doctorate degree in Biological Sciences from Northwestern University.
        • Assistant Professor of Clinical Biochemistry at the University of Toronto, Canada
            With a primary interest in the clinical validation of biomarkers and evaluation of biochemical methods in the clinical laboratory, Paul Yip has been an early collaborator in the development of the Alinity c clinical chemistry analyzer.
          • Professor and Director of the Institute of Clinical Chemistry and Laboratory Medicine at the University Medical Center Mainz, Germany
              Professor Lackner's research interest is focused on cardiovascular disease including thrombosis and haemostasis. He is a former President of the German Society of Clinical Chemistry and Laboratory Medicine (DGKL).
            • Lab Manager, Immuno and Clinical Chemistry Assays, Biopath Laboratory, Paris France
                Jérôme Motol joined Biopath Laboratory in 2012, and now manages all immunoassay and clinical chemistry assay systems. In addition to his role as lab manager, Jérôme leads all internal and external quality management efforts at Biopath, ensuring ISO 15189 document compliance and overseeing new procedure writing.


              DATE: November 28, 2017
              TIME: 06:00am PST, 08:00am CST, 09:00am EST, 3:00pm CEST

              As global healthcare changes, healthcare institutions are being tasked with handling a higher volume of patients, rising costs, and heightened performance pressures. Laboratories, in particular, are under new demands to drive even greater healthcare value with fewer and fewer resources.

              To address such complex and interrelated challenges, Abbott has developed a unified next-generation family of diagnostic systems designed to help labs achieve measurably better healthcare performance across the laboratory: Alinity.

              In this web-series, we’ll learn about Abbott’s multi-pronged, collaborative, and technology-enabled approach and how it shapes the all-new Alinity ci-series clinical chemistry and immunoassay systems. This first discussion with Jennifer Hollenstein, Brittany Dressler, and Jose Santiago, PhD will also share first-look, preliminary data from three Alinity ci-series familiarization sites and explore:

              • The outcome of productivity and reliability studies versus the newly developed Alinity clinical chemistry and immunoassay systems and legacy ARCHITECT systems
              • Perspectives and insights on being one of the first Alinity users from evaluation studies
              • The flexibility of such a compact, scalable system and its ability to boost productivity in a growing private laboratory

              And don’t miss our next series that will look at Alinity ci-series’ features for a better understanding of how it can address your needs and help your lab deliver measurably better healthcare performance.


              *Alinity is only available in select markets and is not commercially available in the US.


              Show Resources
              Show Resources
              Connect with us